- Home
- MURA vs ALGS Comparison
MURA vs ALGS Comparison
Compare MURA & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MURA
- ALGS
- Stock Information
- Founded
- MURA 2013
- ALGS 2018
- Country
- MURA Ireland
- ALGS United States
- Employees
- MURA N/A
- ALGS N/A
- Industry
- MURA
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- MURA
- ALGS Health Care
- Exchange
- MURA Nasdaq
- ALGS Nasdaq
- Market Cap
- MURA 45.8M
- ALGS 53.0M
- IPO Year
- MURA N/A
- ALGS 2020
- Fundamental
- Price
- MURA $2.42
- ALGS $9.13
- Analyst Decision
- MURA Strong Buy
- ALGS Strong Buy
- Analyst Count
- MURA 3
- ALGS 1
- Target Price
- MURA $12.00
- ALGS $70.00
- AVG Volume (30 Days)
- MURA 79.3K
- ALGS 85.7K
- Earning Date
- MURA 08-12-2025
- ALGS 08-05-2025
- Dividend Yield
- MURA N/A
- ALGS N/A
- EPS Growth
- MURA N/A
- ALGS N/A
- EPS
- MURA N/A
- ALGS N/A
- Revenue
- MURA N/A
- ALGS $3,270,000.00
- Revenue This Year
- MURA N/A
- ALGS N/A
- Revenue Next Year
- MURA N/A
- ALGS $51.55
- P/E Ratio
- MURA N/A
- ALGS N/A
- Revenue Growth
- MURA N/A
- ALGS N/A
- 52 Week Low
- MURA $0.95
- ALGS $3.76
- 52 Week High
- MURA $4.74
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- MURA 42.86
- ALGS 59.79
- Support Level
- MURA $2.42
- ALGS $8.18
- Resistance Level
- MURA $2.54
- ALGS $9.44
- Average True Range (ATR)
- MURA 0.09
- ALGS 0.71
- MACD
- MURA -0.00
- ALGS 0.01
- Stochastic Oscillator
- MURA 1.58
- ALGS 65.95
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.